1-4 of 4
Wendim Ghidey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Annemiek Broijl, MDPhD, Marie José Kersten, MD PhD, Wendim Ghidey Alemayehu, PhD, Mark-David Levin, MDPhD, Okke de Weerdt, MD, Edo Vellenga, MDPhD, Ellen Meijer, MDPhD, Shulamiet Wittebol, MDPhD, Rosita Ghiraw-Visser, Marian Stevens-Kroef, PhD, Berna Beverloo, PhD, Gerard M.J. Bos, MDPhD, Pierre W. Wijermans, MDPhD, Henk Lokhorst, MDPhD, Pieter Sonneveld, MDPhD
Journal: Blood
Blood (2014) 124 (21): 4735.
https://doi.org/10.1182/blood.V124.21.4735.4735
Published: 2014
Journal Articles

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Michel Van Gelder, PhD, MD, Wendim Ghidey, Martine ED Chamuleau, MD, Jan Cornelissen, MD, PhD, Eefke J Petersen, MD PhD, Simon M. G. J. Daenen, Pierre Zachee, MD, PhD, Mels Hoogendoorn, MD, PhD, Aart Beker, MD, Gert Jan Timmers, MD, PhD, Arnon P. Kater, MD PhD, Marinus H.J. Van Oers, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2883.
https://doi.org/10.1182/blood.V122.21.2883.2883
Published: 2013
Journal Articles

The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial

Doreen te Raa, MD, Arnon P. Kater, MD PhD, Wendim Ghidey Alemayehu, Alexander Jethwa, Jennifer Hullein, Eric Eldering, PhD, Tatjana Stankovic, MD, PhD, Thorsten Zenz, MD, Christian H Geisler, Marinus H.J. Van Oers, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2861.
https://doi.org/10.1182/blood.V122.21.2861.2861
Published: 2013
Journal Articles

R-DHAP Immuno-Chemotherapy Is An Effective Remission-Induction Treatment for Fludarabine Refractory CLL Patients and Allows the Majority to Proceed to Allogeneic Stem Cell Transplantation. Results of the Planned Interim Analysis of the Dutch-Belgian Prospective Multicenter HOVON88 Trial,

Michel Van Gelder, Wendim Ghidey, Martine ED Chamuleau, MD, Jan J Cornelissen, MD, PhD, Ka Lung Wu, MD, PhD, Mels Hoogendoorn, S. M. G. J. Daenen, Eefke Petersen, MD, Marinus H. J. van Oers
Journal: Blood
Blood (2011) 118 (21): 3911.
https://doi.org/10.1182/blood.V118.21.3911.3911
Published: 2011